Back to GetFilings.com

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002

Commission File Number 001-16407

ZIMMER HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

345 East Main Street, Warsaw, IN 46580
(Address of principal executive offices)
Telephone: (574) 267-6131

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

     Yes [ x ]      No [    ]

At July 31, 2002, there were 194,796,408 shares outstanding of the Registrant’s $.01 par value Common Stock.

1

Table of Contents

ZIMMER HOLDINGS, INC.

INDEX TO FORM 10-Q

June 30, 2002

2

Table of Contents

Part I — Financial Information

Item 1. Financial Statements

ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(unaudited, in millions, except per share data)

The accompanying notes are an integral part of these consolidated financial statements.

3

Table of Contents

ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except per share data)

The accompanying notes are an integral part of these consolidated financial statements.

4

Table of Contents

ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents

ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

     The financial data presented herein is unaudited and should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the three years ended December 31, 2001 included in the annual report on Form 10-K filed by Zimmer Holdings, Inc. (together with all its subsidiaries, the “Company”). In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Results for interim periods should not be considered indicative of results for the full year. Certain amounts in the three and six months ended June 30, 2001 have been reclassified to conform to current year presentation.

     The accompanying consolidated financial statements represent the Company’s consolidated operations as a public company commencing on August 6, 2001, combined with the operations of Zimmer as a division of Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) prior to becoming a public company. For periods prior to August 6, 2001, intercompany accounts with Bristol-Myers Squibb, other than specific outstanding obligations, were combined with invested capital and reported in the consolidated financial statements as net investment in Zimmer.

2. Comprehensive Income

     The reconciliation of net earnings to comprehensive income is as follows:

6

Table of Contents

3. Earnings Per Share

     For periods ended August 6, 2001 and prior, basic and diluted earnings per share are computed using the number of shares of Company common stock outstanding on August 6, 2001, the date all of the shares of Company common stock were distributed to the shareholders of Bristol-Myers Squibb. On the distribution date, outstanding Bristol-Myers Squibb stock options and restricted stock held by Company employees were converted into Company stock options and restricted stock. For periods subsequent to August 6, 2001, any new issuances of common stock are reflected in basic and diluted earnings per share and the dilutive effect of outstanding stock options and restricted stock has been reflected in diluted earnings per share. For the quarter ended June 30, 2002, there were approximately 0.4 million common shares that were not included in the computation of diluted earnings per share since they were anti-dilutive. The following table reconciles the diluted shares used in computing diluted earnings per share:

4. Inventories

7

Table of Contents

5. Property, Plant and Equipment

6. Financial Instruments

     The Company is exposed to market risk due to changes in currency exchange rates. As a result, the Company utilizes foreign exchange forward contracts to offset the effect of exchange rate fluctuations on certain anticipated foreign currency transactions, primarily intercompany sales expected to occur up to twenty-four months in the future. The Company does not hold financial instruments for trading or speculative purposes. For derivatives which qualify as hedges of future cash flows, the effective portion of changes in fair value is temporarily recorded in other comprehensive income, then recognized in earnings when the hedged item affects earnings. The ineffective portion of a derivative’s change in fair value, if any, is reported in earnings. The fair value of derivative instruments recorded on the balance sheet at June 30, 2002 was a net unrealized loss of $8.1 million, or $5.0 million, net of taxes, which is deferred in other comprehensive income and is expected to be reclassified to earnings over the next twenty-four months.

7. Segment Information

     The Company designs, develops, manufactures and markets orthopaedic reconstructive implants, fracture management products, and other products used for orthopaedic and general surgery. Operations are managed through three major geographic areas — the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Asia Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets; and Europe, which is comprised principally of Europe and includes the Middle East and Africa. This structure is the basis for the Company’s reportable segment information discussed below. Segment performance is evaluated based on sales and segment operating profit, exclusive of separation costs and operating expenses pertaining to global operations and corporate expenses. Included in segment operating profit is a cost of capital charge which is offset in global operations. Global operations include U.S. based research, development

8

Table of Contents

engineering, brand management, corporate legal, finance, human resource functions and operations and logistics.

     Net sales and segment operating profit are as follows (in millions):

     Product Category (in millions):

9

Table of Contents

8. Commitments and Contingencies

     The Company is subject to product liability and other claims arising in the ordinary course of business, for which the Company maintains insurance, subject to self-insured retention limits. The Company establishes accruals for product liability and other claims in conjunction with outside counsel based on current information and historical settlement information for open claims, related fees and for claims incurred but not reported. While it is not possible to predict with certainty the outcome of these cases, it is the opinion of management that these cases will not have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

     In addition to product liability, the Company is subject to various other lawsuits and claims arising in the ordinary course of business, none of which are expected to have, upon ultimate resolution, a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

9. Subsequent Events

     Subsequent to June 30, 2002, in connection with its normal risk management activities, the Company entered into foreign exchange forward contracts to purchase U.S. Dollars and sell Euros for an aggregate notional value of $57 million. The contracts, which have been designated as hedges of anticipated foreign currency transactions, contain maturity dates ranging from January 2003 to December 2003 with a weighted average contract rate of USD 0.97 per Euro.

10

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

     Zimmer Holdings, Inc. is a global leader in the design, development, manufacture and marketing of orthopaedic reconstructive implants and fracture management products. Orthopaedic reconstructive implants restore joint function lost due to disease, deformity, or trauma in joints such as knees, hips, shoulders and elbows. Fracture management products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. The Company also manufactures and markets other products relating to orthopaedic and general surgery. With operations in 20 countries and products marketed in approximately 70 countries, operations are managed through three geographic regions — the Americas, Asia Pacific and Europe. As used in this discussion, the “Company” means Zimmer Holdings, Inc. and its subsidiaries.

     For comparison purposes, the unaudited pro forma consolidated statements of earnings for the three and six months ended June 30, 2001 presented herein, have been prepared giving effect to the exclusion of costs incurred by the Company to separate from its former parent and include interest expense on debt expected to be assumed or incurred at the distribution date as if such debt were outstanding from January 1, 2001, as disclosed in previous filings. The unaudited pro forma consolidated statements of earnings for the three and six months ended June 30, 2001 have been derived from the unaudited interim consolidated statements of earnings included herein and do not purport to represent what results of operations actually would have been or to project financial performance for any future periods. The pro forma consolidated statements of earnings reflect all adjustments that, in the opinion of management, are necessary to present fairly the pro forma results of operations. This information should be read in conjunction with the historical consolidated statements of earnings and corresponding notes included elsewhere in this report and in the Company’s Form 10-K for the year ended December 31, 2001. The adjustments to the accompanying historical financial information for the three and six months ended June 30, 2001 are described below:

	(a)		Reflect all costs incurred to date related to the separation of the Company from its former parent. The Company incurred separation costs of $13.1 million and $27.4 million in the three and six months ended June 30, 2001, respectively, related to the separation.
	(b)		Reflect interest expense related to debt expected to be assumed or incurred under the Company’s $600 million credit facility (“Credit Facility”). Assumed average borrowings during the three and six month periods ended June 30, 2001 were $450 million at an average interest rate of 5.5 percent and includes amortization of fees.
	(c)		Reflect the tax effect of the pro forma adjustments for separation costs and interest expense using a rate of 16.2 percent and 22.1 percent for the three and six months ended June 30, 2001, respectively, reflecting the non-deductibility of certain separation costs.

11

Table of Contents

Second Quarter Results of Operations

     The following table sets forth the consolidated results of operations for the three-months ended June 30, 2002 and the as reported and pro forma results of operations for the three-months ended June 30, 2001. The pro forma amounts exclude the effect of costs incurred to separate from the Company’s former parent and include a full quarter of interest expense:

(unaudited, in millions, except per share amounts)

12

Table of Contents

     Net Sales

     Net sales for the three-month period ended June 30, 2002 increased 17 percent to $345.6 million from $294.3 million for the comparable 2001 period. Sales growth reflected strong demand for reconstructive implants and outstanding results in the Americas and Europe segments. This increase was comprised of a 14 percent increase due to incremental volume and changes in the mix of product sales, a 4 percent increase due to higher average selling prices and a 1 percent decrease due to foreign exchange rate fluctuations.

     The following tables set forth net sales by geographic region and product category for the three-months ended June 30, 2002 and 2001 (unaudited, in millions):

Net Sales by Geographic Region

Net Sales by Product Category

     Net sales in the Americas increased 20 percent to $233.9 million in the three-months ended June 30, 2002 compared to the same period in 2001. This increase was comprised of a 15 percent increase due to incremental volume and changes in the mix of product sales, together with a 5 percent increase due to higher average selling prices. Knee sales increased 26 percent led by growth in sales of the NexGen® Legacy® Posterior Stabilized knee, the recently introduced NexGen Legacy Posterior Stabilized Flex knee and the M/G™ Unicompartmental Knee, now featuring Minimally Invasive Solutions ™ (“MIS”) Instrumentation. Hip sales increased 16 percent, driven by continued conversion to VerSys® porous hip stems, the ZMR® Modular Revision Hip System, Trabecular Metal acetabular cups and increased sales of Trilogy® Acetabular System cups incorporating Longevity® Crosslinked Polyethylene Liners. Fracture management product sales increased 17 percent in the quarter in part due to increased

13

Table of Contents

sales of the new Zimmer® Plates and Screws internal fixation devices and TransFx ™ External Fixation Systems.

     Net sales in the Asia Pacific region increased 6 percent to $68.8 million in the three-month period ended June 30, 2002 compared to the same period in 2001. This increase was comprised of an 8 percent increase due to incremental volume and changes in the mix of product sales, a 1 percent increase due to higher average selling prices, offset by a 3 percent decrease due to foreign exchange rate fluctuations. Knee sales increased 9 percent (increased 10 percent constant currency), reflecting continuing strong sales of the NexGen Legacy Posterior Stabilized Flex knee. Hip sales increased 12 percent (increased 15 percent constant currency) driven primarily by strong sales of VerSys porous hip stems, introduction of the ZMR Hip System and sales of Trilogy cups incorporating Longevity Crosslinked Polyethylene Liners. Fracture management product sales decreased 15 percent (decreased 13 percent constant currency) reflecting a decline in M/DN® Intramedullary Fixation sales and sales of compression hip screws.

     Net sales in Europe grew 26 percent to $42.9 million in the three-month period ended June 30, 2002 compared to the same period in 2001, driven by higher sales in France, Germany, Italy, Spain and the United Kingdom. This increase was comprised of a 20 percent increase due to incremental volume and changes in the mix of product sales, a 4 percent increase due to higher average selling prices and a 2 percent increase due to foreign exchange rate fluctuations. Knee sales increased 24 percent (increased 22 percent constant currency) driven by strong sales of the NexGen Legacy system of knee prosthesis as well as the M/G Unicompartmental Knee with MIS instrumentation. Hip sales increased 36 percent (increased 35 percent constant currency) supported by the introduction of ZMR Hip System and increased sales of Trilogy cups incorporating Longevity Crosslinked Polyethylene Liners.

     Overall, worldwide sales of reconstructive implants grew 20 percent (increased 21 percent constant currency) in the three-month period ended June 30, 2002 to $268.2 million compared to $222.9 million during the three-month 2001 period. Knee sales increased 22 percent (increased 22 percent constant currency) in the three-month period ended June 30, 2002 to $148.3 million compared to $121.4 million during the three-month 2001 period. Hip sales increased 17 percent (18 percent constant currency) in the three-month period ended June 30, 2002 to $111.3 million compared to $94.9 million during the three-month 2001 period. Sales of fracture management products increased 6 percent (increased 7 percent constant currency) over the prior year to $33.2 million.

     Gross Profit

     Gross profit as a percentage of net sales was 75.3 percent for the three-month period ended June 30, 2002 compared to 72.3 percent in the comparable 2001 period or 73.6 percent excluding separation costs. The increase in gross margin is due principally to increases in average selling prices realized in all segments. The favorable effect of price increases was partially offset by lower yen hedge gains compared to the same period in the prior year. Other factors contributing to the improvement in gross margin included continued conversion from cemented implants to higher margin porous implants, increased penetration of Longevity®, further penetration into the revision implant category and successful efforts to reduce manufacturing costs through automation, in-sourcing and process improvement. With respect to

14

Table of Contents

the latter, the Company over the past six-months, automated foundry preparation and knee femoral processing, introduced robotics for fracture stem polishing and applied automated laser welding of fiber metal in knees.

     Operating Expenses

     Research and development as a percentage of net sales was 5.6 percent for the three- month period ended June 30, 2002 compared to 5.9 percent for the comparable 2001 period, or 5.6 percent excluding separation costs. Increases in research and development costs kept pace with sales growth, reflecting investments in active and new projects. The Company has many active projects underway focused on areas of strategic significance, including lifestyle designs, revision implants, innovative materials, biotechnology and MIS. Selling, general and administrative expense as a percentage of net sales was 39.9 percent for the three-month period ended June 30, 2002 compared to 43.0 percent for the comparable reported 2001 period or 40.1 percent excluding separation costs. The improvement in the expense ratio reflects a slower growth in expenses than sales growth. The increase in expenses include approximately $1 million of consulting costs associated with tax services and analysis of various external development opportunities. Expenses associated with various strategic initiatives including MIS, direct to consumer advertising, sales force expansion, training and medical education continue to represent important components of the total level of spending on selling, general and administrative expenses.

     Earnings

     Operating profit for the three-month period ended June 30, 2002 increased 50 percent to $103.4 million from $68.9 million in the comparable 2001 period. Excluding separation costs of $13.1 million in the comparable period in 2001, operating profit increased 26 percent from $82.0 million, due primarily to the increase in gross profit margin and operating expenses growing at a slower rate than sales as discussed above.

     The effective tax rate on earnings before taxes decreased to 34.2 percent for the three-month period ended June 30, 2002 from 37.3 percent in the same period in 2001, as computed by the Company’s former parent. Excluding separation costs and including a full quarter of interest expense, the effective tax rate was 35.4 percent for the comparable period in 2001. The Company’s tax rate for the three-months ended June 30, 2002 decreased 130 basis points from 35.5 percent, for the three-months ended March 31, 2002. The Company is implementing business strategies designed to lower tax rates and maximize tax credits. The lower tax rates reflect the early results of these strategies.

     Net earnings increased 53 percent to $65.9 million for the three-month period ended June 30, 2002 compared to $43.2 million in the comparable 2001 period. Basic and diluted earnings per share for the three-month period ended June 30, 2002 increased 55 percent to $0.34 from $0.22 in the comparable 2001 period. Net earnings increased 35 percent from $48.9 million excluding separation costs of $9.7 million, net of tax, and including a full quarter of interest expense, net of tax, of $4.0 million for the same period in 2001. Basic and diluted earnings per share increased 36 percent from $0.25 for the three-months ended June 30, 2001 as adjusted for separation costs and interest expense.

15

Table of Contents

     Operating Profit by Segment

     The following table sets forth operating profit by segment for the three-months ended June 30, 2002 and 2001:

Percent of net sales